The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
The current Trulicity (dulaglutide) supply situation
Eli Lilly has informed us that the limited availability of Trulicity (dulaglutide) will extend to 30 June 2026.
We recommend that patients with type 2 diabetes who are unable to fill their script for Trulicity in time for their next dose should contact their doctor immediately to have their treatment plan reassessed.
We continue to work with Eli Lilly, pharmaceutical wholesalers and medical professional organisations to provide any solutions possible for patients during this shortage.
The TGA will publish updates about the supply of Trulicity from Eli Lilly on the Medicine Shortage Reports Database - external site.
Stay up to date
The worldwide shortage of Trulicity (dulaglutide) is closely related to the shortage of another diabetes medicine, Ozempic (semaglutide). Trulicity is manufactured by pharmaceutical company Eli Lilly. Ozempic is manufactured by another pharmaceutical company, Novo Nordisk.
Since the shortages started, we have received hundreds of messages with comments and questions from people who have been affected, many with similar concerns. We recognise the importance of Trulicity for patients living with diabetes, and we are taking this shortage very seriously.
This page includes answers to questions we have received about the Trulicity shortage.
- Facts about Trulicity
- Why the Trulicity shortage has happened
- What we are doing about the Trulicity shortage
- What we can’t do during a medicine shortage
- Overseas-registered Trulicity is available
- What to do if you can’t get Trulicity
- When will the Trulicity shortage end?
The page is updated immediately when information changes or is added.
Facts about Trulicity
Trulicity is a brand of the medicine called dulaglutide. Trulicity:
- is supplied by pharmaceutical company Eli Lilly
- is a weekly injection
- is an antidiabetic medicine that is different to insulin
- is only approved by us for lowering blood sugar in adults with type 2 diabetes and to reduce the risk of major cardiovascular disease in adults with type 2 diabetes
- is subsidised on the Pharmaceutical Benefits Scheme (PBS) for treatment of type 2 diabetes when certain conditions are met.
You can read more about Trulicity in the Consumer Medicine Information (CMI) - external site.
Why the Trulicity shortage has happened
In June 2022, Eli Lilly told us there was a shortage of Trulicity due to an unexpected increase in demand.
This increase in demand was closely related to the shortage of Ozempic, another diabetes medicine made by a different company. This is because some patients using Ozempic to treat their diabetes were moved to alternate medicines, including Trulicity.
In early 2025, Eli Lilly informed us that the shortage of Trulicity has also been impacted by manufacturing issues.
What we are doing about the Trulicity shortage
Our role in medicine shortages is to reduce the impact on patients where possible. In the Trulicity shortage, we:
- approved suitable overseas medicines that can be used temporarily
- are meeting with the other pharmaceutical company, medical colleges and health professional organisations about how to get Ozempic to the people who need it most, to take the pressure off the supply of Trulicity
- are liaising closely with Eli Lilly and communicating updates on the Medicine Shortage Reports Database - external site.
You can read more about how we manage medicine shortages in the information for consumers section of our website.
What we can't do during a medicine shortage
As pharmaceutical companies are private entities, we can’t force them to make or supply medicines in Australia. We also can’t force them to list their medicines on the PBS or redirect stock from other markets.
Overseas-registered Trulicity products are available
We have granted Eli-Lilly an approval to supply an overseas-registered dulaglutide product, USA-registered Trulicity, temporarily under section 19A of the Therapeutic Goods Act 1989. This product is subsidised under the Pharmaceutical Benefits Scheme (PBS).
More information, including the contact details of the section 19A supplier, is available on the Section 19A approvals database.
What to do if you can't get Trulicity
As there will be limited Trulicity available in Australia until 30 June 2026, you should make an appointment with your doctor as soon as possible to have your type 2 diabetes treatment reassessed if you are unable to fill your script.
There is a range of medicines available to treat type 2 diabetes, and your doctor will be able to advise you about the most appropriate treatment options for you.
This medicine shortage is causing understandable frustration and anxiety throughout the community. Please keep in mind that the health professionals at the medical practices and pharmacies you visit want the best possible health outcomes for everyone, but they do not control the availability of Trulicity. Please do not take your frustration or anger out on your pharmacist or doctor.
When will the Trulicity shortage end?
We don’t expect the Trulicity shortage to end before 30 June 2026.
The TGA is getting regular updates about the availability of Trulicity from Eli Lilly, and we will update this page immediately when the information changes. You can also check the Medicine Shortage Reports Database - external site.